Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00714597 · ClinicalTrials.gov registry record · Phase 3
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 421
- Enrollment target
NCT00714597 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 421 participants.
The verdict
NCT00714597, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 421 participants
- Enrollment target
Study Summary
The primary objective was to compare the efficacy of once daily \[q.d\] subcutaneous \[s.c.\] injections of Semuloparin sodium (AVE5026) with q.d. s.c. injections of Enoxaparin for the primary prevention of Venous Thromboembolic Events \[VTE\] in patients hospitalized for acute medical illness. The secondary objectives were to evaluate the safety of AVE5026 and to document AVE5026 exposure in this population.
Interventions
- DRUG Semuloparin sodium
- DRUG Enoxaparin sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 421 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00714597
The ClinicalTrials.gov registry entry for NCT00714597 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 421 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Semuloparin sodium is the first listed.
NCT00714597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00714597 about?
NCT00714597 is a clinical study titled "Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility". The primary objective was to compare the efficacy of once daily \[q.d\] subcutaneous \[s.c.\] injections of Semuloparin sodium (AVE5026) with q.d. s.c. injections of Enoxaparin for the primary prevention of Venous Thromboembolic Events \[VTE\] in patients hospitalized for acute medical illness. The...
What is the current status of trial NCT00714597?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 421 participants. The study started on 2008-07. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00714597?
The interventions under investigation include: Semuloparin sodium (DRUG), Enoxaparin sodium (DRUG).
Who is sponsoring clinical trial NCT00714597?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.